Artificial intelligence is entering diabetes care in a surprisingly quiet way. Rather than appearing as a chatbot or separate decision-support tool, increasingly sophisticated algorithms are being built into automated insulin delivery systems. Adaptive insulin pump hardware can work with continuous glucose monitor (CGM) data, recent insulin delivery, and changing glucose …
Read More »The Honeymoon Phase Won’t Last Forever: Are We Doing Enough to Preserve Beta Cells?
Receiving a diagnosis of type 1 diabetes can feel overwhelming. Yet for many adults, the weeks or months that follow bring an unexpected twist. Blood glucose levels often become easier to control, insulin needs decrease, and some people wonder if their diabetes is actually improving. This temporary period is known …
Read More »Teaching Muscles to Make Insulin: Could Gene Therapy Rewrite the Future of Type 1 Diabetes?
For more than a century, insulin therapy has remained the cornerstone of treatment for type 1 diabetes. While continuous glucose monitors, insulin pumps, and automated insulin delivery systems have dramatically improved diabetes management, they still do not replace the body’s natural ability to regulate blood sugar. As a result, researchers …
Read More »The Hidden Cost of Diabetes Care: Why Treatment Burden Is Becoming a Clinical Outcome
Managing diabetes has never offered more therapeutic options. Continuous glucose monitors (CGMs), automated insulin delivery systems, GLP-1 receptor agonists, SGLT2 inhibitors, and individualized treatment plans have transformed patient care. Yet despite these advances, many people with diabetes continue to struggle, not because treatments are ineffective, but because the overall workload …
Read More »The Return of C-Peptide: Why This Old Biomarker Is Finding New Clinical Uses
For many years, C-peptide testing was viewed as a simple tool to distinguish type 1 diabetes from type 2 diabetes. However, the story has changed. As researchers gain a better understanding of pancreatic beta-cell function, C-peptide testing in diabetes has become much more valuable than a diagnostic aid alone. Today, …
Read More »Amylin Is Making a Comeback: Why This Forgotten Hormone Is Back in the Spotlight
For years, glucagon-like peptide-1 (GLP-1) receptor agonists have dominated conversations about diabetes and obesity treatment. However, another hormone is quietly returning to the spotlight. Amylin diabetes therapy is making a comeback as researchers develop a new generation of drugs designed to improve blood glucose control and support weight management. Amylin …
Read More »Could “Smart” Insulin End Hypoglycemia? The Race Toward Glucose-Responsive Therapy
For more than a century, insulin has saved millions of lives. Yet despite remarkable advances in diabetes technology, one major challenge remains: preventing hypoglycemia while maintaining excellent glucose control. That is why researchers are developing glucose-responsive insulin, often called “smart” insulin. Instead of delivering a fixed amount of insulin regardless …
Read More »The First Disease-Modifying Treatment After a Type 1 Diabetes Diagnosis: Why Teplizumab Is Changing the Conversation
For decades, treatment after a type 1 diabetes diagnosis focused almost entirely on insulin replacement and blood glucose management. While advances in technology have improved care, clinicians have had few ways to address the autoimmune process driving beta-cell loss. That is beginning to change. With the FDA’s expansion of teplizumab-mzwv …
Read More »Should Patients Still Be Using Flash CGM? Navigating the Shift to Real-Time Monitoring
As diabetes technology continues to evolve, clinicians are increasingly faced with an important question: should patients still be using flash continuous glucose monitoring (CGM), or is it time to switch to real-time CGM? While flash CGM systems have significantly improved glucose monitoring and patient engagement over traditional fingerstick testing, real-time …
Read More »Should Hospitalized Patients Keep Their CGMs and Insulin Pumps? The 2026 Standards Say Yes
For years, hospital admission often meant disconnecting patients from their personal diabetes devices. Continuous glucose monitors (CGMs) and insulin pumps were frequently removed, even when patients had used them successfully at home. However, the 2026 American Diabetes Association (ADA) Standards of Care introduce a significant shift in how hospitals approach …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.